
|Articles|March 1, 2007
FDA grants orphan status to two Lux products
The FDA has granted orphan drug designation to two of Lux Bioscience's investigational therapies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5






















